13. Prevnar 13

Prevnar 13
Prevnar 13 isn't expected to lose patent protection until 2023. (Pfizer)

Prevnar 13
Company: Pfizer
2019 sales: $5.95 billion
Projected 2026 sales: $7.06 billion
Projected CAGR: +2%
Used for: pneumococcal pneumonia

As Pfizer offloads its generic Upjohn unit in a merger with Mylan, the drugmaker will lean on its blockbuster stalwarts as it moves into the next phase. One of those longtime top-sellers, pneumonia vaccine Prevnar 13, could be in for an even brighter future with years of market exclusivity ahead. 

Prevnar hit $5.95 billion in sales in 2019, making it Pfizer's best-selling solo medicine—unlike blood thinner Eliquis, which is co-marketed with Bristol Myers Squibb. In 2026, the year Prevnar loses patent protection, Evaluate Pharma forecasts the shot will rake in $7.06 billion in sales. 

With Prevnar's generic due date on the horizon, Pfizer is aggressively chasing an approval for a Prevnar follow-up. In the meantime, the drugmaker is hoping to lean on its older vaccine to get it over the hump of a possible generics unit spinoff. 

RELATED: Pfizer may look messy post-Upjohn spinoff, but better days could be ahead: analyst

13. Prevnar 13

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.